The United Kingdom and the United States have hammered out a significant trade agreement that will ensure no tariffs on UK medicine products entering the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the NHS. This move ensures that duties on these key products will be held at zero for a period of the next three years.
This deal comes after earlier warnings to dramatically increase duties on patented drug products, with figures floated as high as one hundred percent.
"This arrangement with the Britain reinforces the global environment for new treatments and brings long-overdue balance to transatlantic medicine commerce," a release noted.
Economic Impact
Drugs are one of the UK's biggest goods shipped to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK shipped pharmaceutical products worth billions to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This guarantee safeguards employment, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The pact involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to double total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be capped at 15%. Last year, rebates exceeded twenty percent.
Industry Background
The pact follows a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that American customers were paying several times more for the identical medicines than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been delayed or abandoned, while major expansions have been pledged toward US facilities.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a share of its overall budget over the previous ten-year period.
